These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

489 related articles for article (PubMed ID: 1246307)

  • 1. Combination chemotherapy as an adjuvant treatment in operable breast cancer.
    Bonadonna G; Brusamolino E; Valagussa P; Rossi A; Brugnatelli L; Brambilla C; De Lena M; Tancini G; Bajetta E; Musumeci R; Veronesi U
    N Engl J Med; 1976 Feb; 294(8):405-10. PubMed ID: 1246307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.
    Rivkin SE; Green SJ; Lew D; Costanzi JJ; Athens JW; Osborne CK; Vaughn CB; Martino S
    Cancer; 2003 Jan; 97(1):21-9. PubMed ID: 12491501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-response effect of adjuvant chemotherapy in breast cancer.
    Bonadonna G; Valagussa P
    N Engl J Med; 1981 Jan; 304(1):10-5. PubMed ID: 7432433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.
    Leonard RC; Lind M; Twelves C; Coleman R; van Belle S; Wilson C; Ledermann J; Kennedy I; Barrett-Lee P; Perren T; Verrill M; Cameron D; Foster E; Yellowlees A; Crown J;
    J Natl Cancer Inst; 2004 Jul; 96(14):1076-83. PubMed ID: 15265969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Ancillary chemotherapy with trofosfamid, methotrexate and fluoro-uracil in cancer of the breast (author's transl)].
    Albrecht M; Jepsen G; Trams G; Thomsen K
    Geburtshilfe Frauenheilkd; 1981 Jan; 41(1):1-5. PubMed ID: 7202984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study.
    Mansour EG; Gray R; Shatila AH; Osborne CK; Tormey DC; Gilchrist KW; Cooper MR; Falkson G
    N Engl J Med; 1989 Feb; 320(8):485-90. PubMed ID: 2915651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B.
    Weiss RB; Woolf SH; Demakos E; Holland JF; Berry DA; Falkson G; Cirrincione CT; Robbins A; Bothun S; Henderson IC; Norton L;
    J Clin Oncol; 2003 May; 21(9):1825-35. PubMed ID: 12721260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up.
    Bonadonna G; Valagussa P; Moliterni A; Zambetti M; Brambilla C
    N Engl J Med; 1995 Apr; 332(14):901-6. PubMed ID: 7877646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significance of relapse after adjuvant treatment with combination chemotherapy or 5-fluorouracil alone in high-risk breast cancer. A Western Cancer Study Group Project.
    Chlebowski RT; Weiner JM; Luce J; Hestorff R; Lang JE; Reynolds R; Godfrey T; Ryden VM; Bateman JR
    Cancer Res; 1981 Nov; 41(11 Pt 1):4399-403. PubMed ID: 7306966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surgery and adjuvant chemotherapy in the treatment of operable breast cancer.
    Rossi A; Valagussa P; Bonadonna G
    Prog Clin Biol Res; 1977; 12():391-404. PubMed ID: 335401
    [No Abstract]   [Full Text] [Related]  

  • 11. Adjuvant treatment for early breast cancer: the Ludwig breast cancer studies.
    Goldhirsch A; Gelber R
    NCI Monogr; 1986; (1):55-70. PubMed ID: 3774016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial.
    Overgaard M; Hansen PS; Overgaard J; Rose C; Andersson M; Bach F; Kjaer M; Gadeberg CC; Mouridsen HT; Jensen MB; Zedeler K
    N Engl J Med; 1997 Oct; 337(14):949-55. PubMed ID: 9395428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical analysis of resectable breast cancer: a report of 6 263 cases].
    Yang MT; Rong TH; Huang ZF; Zeng CG; Long H; Fu JH; Lin P; Wang X; Wang SY; Wang X; Tang J
    Ai Zheng; 2005 Mar; 24(3):327-31. PubMed ID: 15757535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse effect of radiotherapy on adjuvant chemotherapy for carcinoma of the breast.
    Holland JF; Glidewell O; Cooper RG
    Surg Gynecol Obstet; 1980 Jun; 150(6):817-21. PubMed ID: 7376042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Adjuvant chemotherapy in breast cancer: status in 1984].
    Jungi WF
    Wien Klin Wochenschr; 1984 Jun; 96(13):486-92. PubMed ID: 6382805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial.
    Ragaz J; Olivotto IA; Spinelli JJ; Phillips N; Jackson SM; Wilson KS; Knowling MA; Coppin CM; Weir L; Gelmon K; Le N; Durand R; Coldman AJ; Manji M
    J Natl Cancer Inst; 2005 Jan; 97(2):116-26. PubMed ID: 15657341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute and late toxicity following adjuvant high-dose chemotherapy for high-risk primary operable breast cancer--a quality assessment study.
    Svane IM; Homburg KM; Kamby C; Nielsen DL; Roer O; Sliffsgaard D; Johnsen HE; Hansen SW
    Acta Oncol; 2002; 41(7-8):675-83. PubMed ID: 14651213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective study of concurrent cyclophosphamide/methotrexate/5-fluorouracil and reduced-dose radiotherapy in patients with early-stage breast carcinoma.
    Bellon JR; Shulman LN; Come SE; Li X; Gelman RS; Silver BJ; Harris JR; Recht A
    Cancer; 2004 Apr; 100(7):1358-64. PubMed ID: 15042668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma.
    Cocconi G; Di Blasio B; Boni C; Bisagni G; Ceci G; Rondini E; Bella M; Leonardi F; Savoldi L; Camisa R; Bruzzi P
    Cancer; 2002 Jul; 95(2):228-35. PubMed ID: 12124820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of extracapsular tumor spread for locoregional control in premenopausal patients with node-positive breast cancer treated with classical cyclophosphamide, methotrexate, and fluorouracil: long-term observations from International Breast Cancer Study Group Trial VI.
    Gruber G; Bonetti M; Nasi ML; Price KN; Castiglione-Gertsch M; Rudenstam CM; Holmberg SB; Lindtner J; Golouh R; Collins J; Crivellari D; Carbone A; Thürlimann B; Simoncini E; Fey MF; Gelber RD; Coates AS; Goldhirsch A;
    J Clin Oncol; 2005 Oct; 23(28):7089-97. PubMed ID: 16192592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.